Tag: genomics
-
Advanced Encryption Shown to Enable Cancer Data Sharing
Data scientists and cancer specialists demonstrate a data encryption technique that makes possible real-world cancer data sharing while preserving individual privacy.
-
Regeneron Acquires Hearing Loss Biotech in $213M Deal
Regeneron Pharmaceuticals, a maker of synthetic biologic treatments, is acquiring Decibel Therapeutics, developer of gene therapies to treat hearing loss and balance disorders.
-
Companies to Assess Ovarian Health Biotech Drug
A women’s health biotechnology company is partnering with a Brazilian drug maker to evaluate a precision target and treatment for ovarian health disorders.
-
Companies Partner on Fast Production of Biologics in Plants
The developer of a biologic drug-making process with engineered plant crops is collaborating with a vertical farming company to create a network of biologics production facilities.
-
Streamlined Gene Therapy Delivery Process Demonstrated
A group of academic and industry researchers exhibited in lab cells and mice a more direct delivery technique that could make gene therapies more accessible and inexpensive.
-
One-Time Crispr HIV Therapy Given Fast-Track Status
A treatment for HIV taken just once, using the genome-editing technology Crispr, is receiving fast-track designation from the U.S. Food and Drug Administration.
-
Darpa Seeking On-Demand, Distributed Production of Proteins
A synthetic biology company is receiving a contract with the U.S. advanced defense research agency to devise a high-speed localized process for making therapeutic proteins.
-
NIH Funding Single Home Test for Covid-19, Influenza, RSV
A developer of diagnostics for infectious and other diseases is receiving a National Institutes of Health contract to advance a single at-home test for multiple respiratory diseases.
-
Synthetic DNA Company Gains $10M in Venture Round
A company using a process it says can produce synthetic genes with greater accuracy for research and clinical applications is raising $10 million in its first venture round.
-
Engineered T-Cells Shown Safe, Reduce Myasthenia Gravis
Results of a small clinical trial show genetically altered T-cells from patients with myasthenia gravis are well tolerated and reduce symptoms of the disease.